header-18
About Us

Lidija Jovanovic

Lidija Jovanovic

Positions

  • Postdoctoral Research Fellow, APCRC-Q
  • Member, IHBI, QUT

Contact Details

Phone
+61 7 3443 7265

Qualifications

  • PhD, Molecular Pathology, Otago University, New Zealand, 2006
  • BSc (Hons) 1st Class, Biology, University of Belgrade, Yugoslavia, 1988

Biography

Dr Jovanovic is a molecular scientist who obtained her degrees from the University of Belgrade, Yugoslavia and the University of Otago, New Zealand. She completed her PhD investigating clonal origins and molecular phenotypes in multiple and histologically diverse tumours in multifocal papillary thyroid carcinoma. Her postdoctoral research focused on markers of progression in prostate cancer and molecular characterization of synchronous clear cell/papillary renal carcinomas.

Dr Jovanovic joined the Australian Prostate Cancer Research Centre – Queensland in March 2009 where she works on the characterisation of multifocality in prostate carcinoma and the biology of prostate cancer circulating tumour cells, in the area of molecular pathology.

Research interests

prostate carcinoma, multifocality, circulating tumour cells, molecular pathology

Current research projects

Biomarkers

  • Identify Biomarkers to Discriminate Indolent from Aggressive Prostate Cancer and mechanisms of Therapeutic Resistance

 

Clinical Research

  • EVERSUN:  A phase 2 trial of EVERolimus alternating with SUNitinib as first line therapy for advanced renal cell carcinoma - ANZUP Protocol Number:  ANZUP 0901
  • Circulating tumour Cells and Protein Biomarkers in Patients with High Risk Localised Prostate Cancer:  Baseline Levels, Response to therapy and Prognostic and Predictive Significance
  • Analysis of Biomarkers from Circulating Tumour Cells and Exosomes to Monitor Prostate Cancer Progression and Treatment Resistance

Top publications

  • Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Grebe SKG. Thyroid gland clonality revisited: the embryonal patch size of the normal human thyroid gland is very large, suggesting X-chromosome inactivation tumor clonality studies of thyroid tumors have to be interpreted with caution. Journal of Clinical Endocrinology and Metabolism. 2003; 88 (7): 3284-3291
  • Jovanovic L, Delahunt B, McIver B, Eberhardt NL Bhattacharya A, Lea R, Grebe SKG. Distinct genetic changes characterise multifocality and diverse histological subtypes in papillary thyroid carcinoma. Pathology. 2010; 42 (6): 524-33
  • Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Grebe SKG. Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. Journal of Pathology 2008; 215 (2): 145-154
  • Hajdukovic-Dragojlovic L, Nesic M, Cuperlovic M, Movsesian M, Dovezenski N, Milosevic-Jovcic N, Jovanovic L. Regulatory, effectory and accessory cells of the immune response: A study of human immunoglobulins (IgG and IgE) glycosylation by interaction with lectins. In Immunoregulation in health and disease. Lukic M, Colic M, Mostarica-Stojakovic M, Cuperlovic K (Eds). Academic Press, Inc: California, 1997; 221-234
  • Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Grebe SKG. Optimising restriction enzyme cleavage of DNA derived from archival histopathological samples: an improved HUMARA assay. Pathology. 2003; 35 (1): 70-74

Team

Collaborators

  • Melanie Lehman, Prostate Centre, University of British Columbia
  • Margot Lehman, PAH, QLD Health
  • Jarad Martin, St. Andrew's Toowoomba Hospital
  • Michael Fanning, PAH, QLD Health
  • Sonia Yip, NHMRC Clinical Trials Centre, The University of Sydney

Professional memberships and associations

American Society for Cancer Research